A Phase 4 interventional study of Ocrelizumab in Multiple Sclerosis and Clinically Isolated Syndrome, sponsored by Hoffmann-La Roche. Completed at 11 sites in 5 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.
Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 19th largest by enrollment, is one of 4 that started in 2022, is one of 11 in phase 4, and was the 17th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
Hoffmann-La Roche · Sites in Bulgaria, France, Germany and 3 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2022.
This study's enrollment of 70 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 170 across the 27 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 27 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
35 studies in Multiple Sclerosis by Hoffmann-La Roche: 6 open now, 17 under way, 7 of them phase 3. Of 14 finished, 7 (50%) have results posted.
Among the 35 studies in Multiple Sclerosis by Hoffmann-La Roche, this one is the 24th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2022, is one of 6 in phase 4, and was the 20th registered.
Hoffmann-La Roche’s Multiple Sclerosis studies by the year they started, since 2004.
1 of the studies testing ocrelizumab in Multiple Sclerosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04466150University of California, San FranciscoImpact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing ocrelizumab in Multiple Sclerosis, from their registry updates:
Among Hoffmann-La Roche’s 35 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the potential placental transfer of ocrelizumab in pregnant women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] whose last dose of ocrelizumab was administered any time from 6 months before the last menstrual period (LMP) through to the first trimester (up to gestational week 13) of pregnancy, and the corresponding pharmacodynamic effects (B cell levels) in the infant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pregnant women with CIS or MS (in line with the locally approved indications) receiving commercial ocrelizumab up to 6 months before the LMP or during the first trimester of pregnancy (up to gestational week 13), due to accidental exposure, or in whom a decision to treat with ocrelizumab was taken as part of routine clinical practice.
Drug: Ocrelizumab
Infants born to women receiving commercial ocrelizumab IV either 0-6 months before the LMP or during the first trimester of pregnancy (up to gestational week 13) due to accidental exposure, or in whom a decision to treat with ocrelizumab was taken as part of routine clinical practice were observed up to month 13 of age.
Post-partum dosing and treatment duration are at the discretion of the physicians, in accordance with local clinical practice and local labelling.
Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN)
The event rate (percentage of infants with B cell levels below LLN) and corresponding Clopper Pearson 95% CI were reported. B-cell reference ranges by week of life (absolute counts) are defined by Borriello et al. 2022.
Time frame: At Week 6 of infant's life
Absolute CD19+ B Cell Count in the Infant Potentially Exposed to Ocrelizumab During Pregnancy
Time frame: At Week 6 of infant's life
Percentage of CD19+ B Cell in the Infant Potentially Exposed to Ocrelizumab During Pregnancy
Time frame: At Week 6 of infant's life
Serum Concentration of Ocrelizumab in the Umbilical Cord Blood at Birth
Serum ocrelizumab concentrations were measured in the umbilical cord blood at birth (within 1 hour after delivery) to evaluate whether there was placental transfer of ocrelizumab from the mother to the infant. At delivery, blood samples from the umbilical cord were collected. Ocrelizumab serum concentration below the lower limit of quantification (LLOQ = 156 ng/ml) was set to zero.
Time frame: Within 1 hour after delivery (at birth, Day 1)
Serum Concentration of Ocrelizumab in the Infant at Week 6 of Life
Serum ocrelizumab concentrations were measured were measured at 6 weeks of the infants life to evaluate whether there was placental transfer of ocrelizumab from the mother to the infant. Serum samples from the infant were collected.
Time frame: At Week 6 of infant's life
Serum Concentration of Ocrelizumab in the Mother
Serum concentration of ocrelizumab in the mother during pregnancy (time frame of blood sampling: Week 24-30, Week 35) and at delivery (time frame of blood sampling: within 24 hours after delivery). Ocrelizumab serum concentration below the lower limit of quantification (LLOQ = 156 ng/ml) was set to zero.
Time frame: Baseline (gestational Weeks 24-30), gestational Week 35, and at delivery (within 24 hours after delivery) (at birth, Day 1)
Percentage of Infants With Adverse Events
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Percentages have been rounded off.
Time frame: Up to approximately 71 weeks
Percentage of Mothers With Adverse Events
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Percentages have been rounded off.
Time frame: Up to approximately 87.6 weeks
Infant Characteristics at Birth: Body Weight
Day 1 refers to the time an infant's birth.
Time frame: At birth (Day 1)
Infant Characteristics at Birth: Head Circumference
Day 1 refers to the time an infant's birth.
Time frame: At birth (Day 1)
Infant Characteristics at Birth: Body Length
Day 1 refers to the time an infant's birth.
Time frame: At birth (Day 1)
Percentage of Pregnancies Resulting in Live Births, Therapeutic Abortions, or Stillbirth
Pregnancy outcomes analysed included live births (term and preterm, presence of congenital anomalies) and elective/therapeutic abortions and stillbirths.
Time frame: During pregnancy (anytime between 37 to 42 weeks of gestation) and at birth (at Day 1)
Mean Titers of Measles, Immunoglobin G (IgG) Antibody in Response to MMR Vaccination
The immune response to MMR vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. mIU/mL=milli-international units per milliliter.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Mumps, IgG Antibody in Response to MMR Vaccination
The immune response to MMR vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. RU/mL=relative units per milliliter.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Rubella, IgG Antibody in Response to MMR Vaccination
The immune response to MMR vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. IU/mL=international units per milliliter.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Percentage of Infants With Positive Humoral Response to MMR Vaccination
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) are presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for MMR vaccine are as follows: Anti-Measles Vir IgG(-70)CL: ≥ 120 mIU/mL; Anti-MumpsAT Vir iGG(-70)CL: ≥ 17 U/mL; Anti-Rub Vir IgG(-70)RUOCL: ≥ 10 IU/mL. Percentages have been rounded off.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Corynebacterium Diphtheriae, IgG Antibody in Response to Diphtheria-Tetanus-Pertussis (DTP) Vaccination
The immune response to DTP vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Bordetella Pertussis, IgG Antibody in Response to DTP Vaccination
The immune response to DTP vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. Cut-off Index (COI) = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative; * COI 0.95-1.04: Equivocal; * COI \> 1.04: Positive. The assay used has not been standardized against WHO International Units (IU/mL) for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Tetanus Toxoid, IgG Antibody in Response to DTP Vaccination
The immune response to DTP vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Percentage of Infants With Positive Humoral Response to DTP Vaccination
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for DTP vaccine are as follows: Anti-Diphtheria IgG(-70)CL and Anti-Tetanus Toxoid IgG(-70)RUO: ≥ 0.01 IU/mL; Bordetella pertussis antibodies, IgG: \> 1.04 COI. COI = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative; * COI 0.95-1.04: Equivocal; * COI \> 1.04: Positive. The assay used has not been standardized against WHO international units for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Antibody Immune Responses to Haemophilus Influenzae Type B (Hib) Vaccination
The immune response to Hib vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Percentage of Infants With Positive Humoral Response to Hib Vaccination
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) will be presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for Hib vaccine are as follows: Hib, IgG: ≥ 0.15 µg/mL.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Antibody Immune Responses to Hepatitis B Virus (HBV) Vaccination
The immune response to HBV vaccination will be assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine is not planned to be administered. This is to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Percentage of Infants With Positive Humoral Response to HBV Vaccination
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for the IgG antibody titer. Seroprotective titer based on vaccine tests for HBV vaccine are as follows: Anti-HBs: ≥ 10 mIU/mL.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Mean Titers of Antibody Immune Responses to 13-valent Pneumococcal Conjugate (PCV-13) Vaccination
The immune response to PCV-13 vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Percentage of Infants With Positive Humoral Response to PCV-13 Vaccination
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for PCV-13 vaccine are as follows: 13 Valent anti-pneumococcal antibody panel: ≥ 0.35 µg/ml. Percentages have been rounded off.
Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
35 pregnant women (with singleton pregnancy) were enrolled in the study across 10 centers in the United States, Germany, France, Switzerland and Spain from 13 April 2022 to 14 July 2025. An Informed Consent Form (ICF) for participation of the maternal subject and her unborn was signed and dated by the subject. Where applicable, the written ICF with respect to the infant was also signed and dated by the holder of parental rights as designated by the maternal subject.
| Milestone | Women | Infants |
|---|---|---|
| Started | 35 | 35 |
| Subject gave birth/infant was born | 35 | 35 |
| Completed | 33 | 34 |
| Not completed | 2 | 1 |
| Withdrew: Participant switches to another treatment of ms | 1 | 0 |
| Withdrew: Reason not specified | 1 | 1 |
| Milestone | Women | Infants |
|---|---|---|
| Started | 33 | 34 |
| Completed | 32 | 33 |
| Not completed | 1 | 1 |
| Withdrew: Reason not specified | 1 | 1 |
The event rate (percentage of infants with B cell levels below LLN) and corresponding Clopper Pearson 95% CI were reported. B-cell reference ranges by week of life (absolute counts) are defined by Borriello et al. 2022.
| percentage of participants | Infants |
|---|---|
| Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) | 0 (0 to 10.28) |
| cells per microliter (cells/µL) | Infants |
|---|---|
| Absolute CD19+ B Cell Count in the Infant Potentially Exposed to Ocrelizumab During Pregnancy | 1170.00 (269.0 to 2408.0) |
| percentage of cells | Infants |
|---|---|
| Percentage of CD19+ B Cell in the Infant Potentially Exposed to Ocrelizumab During Pregnancy | 19.20 (5.2 to 35.3) |
Serum ocrelizumab concentrations were measured in the umbilical cord blood at birth (within 1 hour after delivery) to evaluate whether there was placental transfer of ocrelizumab from the mother to the infant. At delivery, blood samples from the umbilical cord were collected. Ocrelizumab serum concentration below the lower limit of quantification (LLOQ = 156 ng/ml) was set to zero.
| nanograms/milliliter (ng/mL) | Infants |
|---|---|
| Serum Concentration of Ocrelizumab in the Umbilical Cord Blood at Birth | 0.00 (0.0 to 694.0) |
Serum ocrelizumab concentrations were measured were measured at 6 weeks of the infants life to evaluate whether there was placental transfer of ocrelizumab from the mother to the infant. Serum samples from the infant were collected.
| ng/mL | Infants |
|---|---|
| Serum Concentration of Ocrelizumab in the Infant at Week 6 of Life | 0.00 (0.0 to 263.0) |
Serum concentration of ocrelizumab in the mother during pregnancy (time frame of blood sampling: Week 24-30, Week 35) and at delivery (time frame of blood sampling: within 24 hours after delivery). Ocrelizumab serum concentration below the lower limit of quantification (LLOQ = 156 ng/ml) was set to zero.
| ng/mL | Women |
|---|---|
| Baseline - Gestational Weeks 24-30 | 0.00 (0.0 to 9090.0) |
| Gestational Week 35 | 0.00 (0.0 to 787.0) |
| At Delivery | 0.00 (0.0 to 382.0) |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Percentages have been rounded off.
| percentage of infants | Infants |
|---|---|
| Percentage of Infants With Adverse Events | 82.9 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Percentages have been rounded off.
| percentage of mothers | Women |
|---|---|
| Percentage of Mothers With Adverse Events | 94.3 |
Day 1 refers to the time an infant's birth.
| kilogram (kg) | Infants |
|---|---|
| Infant Characteristics at Birth: Body Weight | 3.46 ± 0.43 |
Day 1 refers to the time an infant's birth.
| centimeter (cm) | Infants |
|---|---|
| Infant Characteristics at Birth: Head Circumference | 35.08 ± 1.15 |
Day 1 refers to the time an infant's birth.
| cm | Infants |
|---|---|
| Infant Characteristics at Birth: Body Length | 51.58 ± 2.15 |
Pregnancy outcomes analysed included live births (term and preterm, presence of congenital anomalies) and elective/therapeutic abortions and stillbirths.
| percentage of pregnancies | Women |
|---|---|
| Live Births | 100 |
| Congenital Anomalies | 8.6 |
| Therapeutic Abortions | 0 |
| Stillbirth | 0 |
| Preterm | 0 |
The immune response to MMR vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. mIU/mL=milli-international units per milliliter.
| mIU/mL | Infants |
|---|---|
| Mean Titers of Measles, Immunoglobin G (IgG) Antibody in Response to MMR Vaccination | 2697.43 ± 2124.74 |
The immune response to MMR vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. RU/mL=relative units per milliliter.
| RU/mL | Infants |
|---|---|
| Mean Titers of Mumps, IgG Antibody in Response to MMR Vaccination | 94.37 ± 62.56 |
The immune response to MMR vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. IU/mL=international units per milliliter.
| IU/mL | Infants |
|---|---|
| Mean Titers of Rubella, IgG Antibody in Response to MMR Vaccination | 137.57 ± 96.30 |
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) are presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for MMR vaccine are as follows: Anti-Measles Vir IgG(-70)CL: ≥ 120 mIU/mL; Anti-MumpsAT Vir iGG(-70)CL: ≥ 17 U/mL; Anti-Rub Vir IgG(-70)RUOCL: ≥ 10 IU/mL. Percentages have been rounded off.
| percentage of infants | Infants |
|---|---|
| Measles, IgG | 96.4 |
| Mumps, IgG | 90.0 |
| Rubella, IgG | 96.3 |
The immune response to DTP vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
| IU/mL | Infants |
|---|---|
| Mean Titers of Corynebacterium Diphtheriae, IgG Antibody in Response to Diphtheria-Tetanus-Pertussis (DTP) Vaccination | 1.02 ± 1.35 |
The immune response to DTP vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. Cut-off Index (COI) = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative; * COI 0.95-1.04: Equivocal; * COI \> 1.04: Positive. The assay used has not been standardized against WHO International Units (IU/mL) for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).
| COI | Infants |
|---|---|
| Mean Titers of Bordetella Pertussis, IgG Antibody in Response to DTP Vaccination | 1.45 ± 1.12 |
The immune response to DTP vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
| IU/mL | Infants |
|---|---|
| Mean Titers of Tetanus Toxoid, IgG Antibody in Response to DTP Vaccination | 4.34 ± 5.27 |
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for DTP vaccine are as follows: Anti-Diphtheria IgG(-70)CL and Anti-Tetanus Toxoid IgG(-70)RUO: ≥ 0.01 IU/mL; Bordetella pertussis antibodies, IgG: \> 1.04 COI. COI = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative; * COI 0.95-1.04: Equivocal; * COI \> 1.04: Positive. The assay used has not been standardized against WHO international units for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).
| percentage of infants | Infants |
|---|---|
| Corynebacterium Diphtheriae, IgG | 100 |
| Bordetella Pertussis, IgG | 58.6 |
| Clostridium Tetani Toxoid, IgG | 100 |
The immune response to Hib vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
| microgram per milliliter (ug/mL) | Infants |
|---|---|
| Mean Titers of Antibody Immune Responses to Haemophilus Influenzae Type B (Hib) Vaccination | 2.99 ± 3.55 |
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) will be presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for Hib vaccine are as follows: Hib, IgG: ≥ 0.15 µg/mL.
| percentage of infants | Infants |
|---|---|
| Percentage of Infants With Positive Humoral Response to Hib Vaccination | 82.8 |
The immune response to HBV vaccination will be assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine is not planned to be administered. This is to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
| mIU/mL | Infants |
|---|---|
| Mean Titers of Antibody Immune Responses to Hepatitis B Virus (HBV) Vaccination | 2101.83 ± 3166.80 |
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for the IgG antibody titer. Seroprotective titer based on vaccine tests for HBV vaccine are as follows: Anti-HBs: ≥ 10 mIU/mL.
| percentage of infants | Infants |
|---|---|
| Percentage of Infants With Positive Humoral Response to HBV Vaccination | 94.7 |
The immune response to PCV-13 vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.
| ug/mL | Infants |
|---|---|
| Pneumococcal Capsular Polysaccharide, Serotype 1, IgG | 3.63 ± 9.40 |
| Pneumococcal Capsular Polysaccharide, Serotype 14, IgG | 5.89 ± 5.77 |
| Pneumococcal Capsular Polysaccharide, Serotype 18C, IgG | 3.29 ± 5.15 |
| Pneumococcal Capsular Polysaccharide, Serotype 19A, IgG | 1.33 ± 2.63 |
| Pneumococcal Capsular Polysaccharide, Serotype 19F, IgG | 14.01 ± 33.90 |
| Pneumococcal Capsular Polysaccharide, Serotype 23F, IgG | 4.77 ± 7.62 |
| Pneumococcal Capsular Polysaccharide, Serotype 3, IgG | 1.92 ± 3.41 |
| Pneumococcal Capsular Polysaccharide, Serotype 4, IgG | 3.48 ± 8.18 |
| Pneumococcal Capsular Polysaccharide, Serotype 5, IgG | 3.23 ± 7.32 |
| Pneumococcal Capsular Polysaccharide, Serotype 6A, IgG | 10.42 ± 19.67 |
| Pneumococcal Capsular Polysaccharide, Serotype 6B, IgG | 5.51 ± 7.69 |
| Pneumococcal Capsular Polysaccharide, Serotype 7F, IgG | 3.06 ± 3.44 |
| Pneumococcal Capsular Polysaccharide, Serotype 9V, IgG | 2.19 ± 3.71 |
Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for PCV-13 vaccine are as follows: 13 Valent anti-pneumococcal antibody panel: ≥ 0.35 µg/ml. Percentages have been rounded off.
| percentage of infants | Infants |
|---|---|
| Pneumococcal Capsular Polysaccharide, Serotype 1, IgG | 74.1 |
| Pneumococcal Capsular Polysaccharide, Serotype 14, IgG | 96.3 |
| Pneumococcal Capsular Polysaccharide, Serotype 18C, IgG | 77.8 |
| Pneumococcal Capsular Polysaccharide, Serotype 19A, IgG | 51.9 |
| Pneumococcal Capsular Polysaccharide, Serotype 19F, IgG | 92.6 |
| Pneumococcal Capsular Polysaccharide, Serotype 23F, IgG | 85.2 |
| Pneumococcal Capsular Polysaccharide, Serotype 3, IgG | 59.3 |
| Pneumococcal Capsular Polysaccharide, Serotype 4, IgG | 77.8 |
| Pneumococcal Capsular Polysaccharide, Serotype 5, IgG | 70.4 |
| Pneumococcal Capsular Polysaccharide, Serotype 6A, IgG | 92.6 |
| Pneumococcal Capsular Polysaccharide, Serotype 6B, IgG | 88.9 |
| Pneumococcal Capsular Polysaccharide, Serotype 7F, IgG | 85.2 |
| Pneumococcal Capsular Polysaccharide, Serotype 9V, IgG | 74.1 |
Collected over Infants: Up to approximately 71 weeks Mothers: Up to approximately 87.6 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Women | 0/35 (0%) | 6/35 (17.1%) | 28/35 (80%) |
| Infant | 0/35 (0%) | 3/35 (8.6%) | 26/35 (74.3%) |
| Event | Women | Infant |
|---|---|---|
| Premature separation of placentaPregnancy, puerperium and perinatal conditions | 2/35 | 0/35 |
| Neonatal respiratory failureRespiratory, thoracic and mediastinal disorders | 0/35 | 2/35 |
| Cholecystitis acuteHepatobiliary disorders | 1/35 | 0/35 |
| Neonatal infectionInfections and infestations | 0/35 | 1/35 |
| Post procedural infectionInfections and infestations | 1/35 | 0/35 |
| Respiratory syncytial virus infectionInfections and infestations | 0/35 | 1/35 |
| Postpartum haemorrhagePregnancy, puerperium and perinatal conditions | 1/35 | 0/35 |
| Uterine inflammationReproductive system and breast disorders | 1/35 | 0/35 |
| Event | Women | Infant |
|---|---|---|
| COVID-19Infections and infestations | 8/35 | 6/35 |
| Ear infectionInfections and infestations | 0/35 | 7/35 |
| NasopharyngitisInfections and infestations | 4/35 | 7/35 |
| Infusion related reactionInjury, poisoning and procedural complications | 7/35 | 0/35 |
| ConjunctivitisInfections and infestations | 3/35 | 6/35 |
| DiarrhoeaGastrointestinal disorders | 0/35 | 5/35 |
| PyrexiaGeneral disorders | 1/35 | 5/35 |
| BronchitisInfections and infestations | 0/35 | 5/35 |
| Iron deficiencyMetabolism and nutrition disorders | 5/35 | 0/35 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/35 | 4/35 |
Full analysis set women (FASW) included all enrolled pregnant women who were exposed to ocrelizumab either 0-6 months before the LMP or in the first trimester of pregnancy. Full analysis set infants (FASI) included all infants born to women in the FASW who were potentially exposed to ocrelizumab during pregnancy. As consent for race and ethnicity was not obtained, this data has not been reported.
| Age, Customized(Participants) | Women | Infants | Total |
|---|---|---|---|
| Preterm newborn infants (gestational age <37 weeks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 35 | 35 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 35 | 0 | 35 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Women | Infants | Total |
|---|---|---|---|
| Female | 35 | 22 | 57 |
| Male | 0 | 13 | 13 |
| Race/Ethnicity, Customized(Participants) | Women | Infants | Total |
|---|---|---|---|
| Not reported | 35 | 35 | 70 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2022 to primary completion in Apr 2024, 23 months.
Results were first posted in May 2025, 1 year 1 month after primary completion.
Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 23 months is below that.
Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab